Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Roeland E Wasmann; Cornelis Smit; Eric P H van Dongen; René M J Wiezer; Jill Adler-Moore; Yvo M de Beer; David M Burger; Catherijne A J Knibbe; Roger J M Brüggemann

doi:10.1093/cid/ciz885

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Roeland E Wasmann^*, Cornelis Smit, Eric P H van Dongen, René M J Wiezer, Jill Adler-Moore, Yvo M de Beer, David M Burger, Catherijne A J Knibbe, Roger J M Brüggemann

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Web of Science)

Abstract

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

Original language	English
Article number	ciz885
Pages (from-to)	2213-2215
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	70
Issue number	10
Early online date	7 Sep 2019
DOIs	https://doi.org/10.1093/cid/ciz885
Publication status	Published - 15 May 2020

Keywords

fungal treatment
fungal infection
obese
population pharmacokinetics
optimal dosing
POPULATION PHARMACOKINETICS
PHARMACODYNAMICS
DEOXYCHOLATE
AMBISOME
WEIGHT
SAFETY

Access to Document

10.1093/cid/ciz885Licence: CC BY-NC-ND

Cite this

@article{3dd33d024835442b8ee4c5ab7db5f1bc,

title = "Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals",

abstract = "In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.",

keywords = "fungal treatment, fungal infection, obese, population pharmacokinetics, optimal dosing, POPULATION PHARMACOKINETICS, PHARMACODYNAMICS, DEOXYCHOLATE, AMBISOME, WEIGHT, SAFETY",

author = "Wasmann, {Roeland E} and Cornelis Smit and {van Dongen}, {Eric P H} and Wiezer, {Ren{\'e} M J} and Jill Adler-Moore and {de Beer}, {Yvo M} and Burger, {David M} and Knibbe, {Catherijne A J} and Br{\"u}ggemann, {Roger J M}",

note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2020",

month = may,

day = "15",

doi = "10.1093/cid/ciz885",

language = "English",

volume = "70",

pages = "2213--2215",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

AU - Wasmann, Roeland E

AU - Smit, Cornelis

AU - van Dongen, Eric P H

AU - Wiezer, René M J

AU - Adler-Moore, Jill

AU - de Beer, Yvo M

AU - Burger, David M

AU - Knibbe, Catherijne A J

AU - Brüggemann, Roger J M

N1 - © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2020/5/15

Y1 - 2020/5/15

N2 - In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

AB - In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

KW - fungal treatment

KW - fungal infection

KW - obese

KW - population pharmacokinetics

KW - optimal dosing

KW - POPULATION PHARMACOKINETICS

KW - PHARMACODYNAMICS

KW - DEOXYCHOLATE

KW - AMBISOME

KW - WEIGHT

KW - SAFETY

U2 - 10.1093/cid/ciz885

DO - 10.1093/cid/ciz885

M3 - Article

C2 - 31588493

VL - 70

SP - 2213

EP - 2215

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

M1 - ciz885

ER -